NASDAQ: TECH · Biotechnology
Bio-Techne (TECH) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Bio-Techne (TECH) at $65.76 a share. The stock last closed at $72.79, which puts the model's fair value 9.7% below the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 16 Nov 2026. Bio-Techne Corporation.
The report adds the live price, the price chart, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $65.04 to $65.76 (+1.1%). Analysts raised their next-twelve-month EBITDA estimates: most of the move.
What the model makes of itThe price of $72.79 is 9.7% above it: Fairly valued, on a high evidence grade.
What's nextNext report on 2 Feb 2027. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give TECH?
The calibrated range for TECH over 63 trading days is $52.59 to $78.12. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 13,250 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $52.93 to $81.53. In 34% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Bio-Techne Corporation (TECH) is a healthcare company in biotechnology. Together with its subsidiaries, it develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
Faircurve's model put the fair value at $65.76 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $65.04, so the fair value moved +1.1%. In the model's words, analysts raised their next-twelve-month EBITDA estimates: most of the move. The calibrated range over 63 trading days is $52.59 to $78.12. It is built from the fair value, as there is no live options data for the stock, and calibrated weekly against realised prices (13,250 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The evidence grade is High. It covers input completeness, comparable companies and the spread of outcomes, not whether the fair value is right.
The overall quality score is 57 out of 100 against comparable companies. Balance sheet stands out at 93, with net debt to EBITDA of -0.20x against a peer median of 2.26x. Profitability is 69, with ROIC of 8.7% against a peer median of 3.6%. Growth quality is 25, with trailing revenue growth of -0.4% against a peer median of 5.7%. The comparable companies are BioMarin Pharmaceutical Inc. (BMRN), TG Therapeutics, Inc. (TGTX), Protagonist Therapeutics, Inc. (PTGX) and Neurocrine Biosciences, Inc. (NBIX).
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does TECH report earnings, and how has the stock reacted?
Bio-Techne's next earnings report is scheduled for 2 Feb 2027. Companies can move their dates.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across TECH's last 8 reports, ignoring direction, was 0.2%.
What the options market has priced for a month's move in TECH
How does TECH score on business quality?
Bio-Techne's overall quality score is 57 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 69 | 8.7%ROIC | 3.6% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 60 | 1.79xFCF / net income | 1.51x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 25 | -0.4%Revenue growth, trailing | 5.7% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 55 | 0.4%Net buybacks / market value | 0.9% |
| Balance sheetNet debt to EBITDA and interest coverage. | 93 | -0.20xNet debt / EBITDA | 2.26x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 45 | 5.8 ptsEBITDA margin downside volatility, 5y | 5.6 pts |
How does TECH compare with similar companies?
The companies in biotechnology closest to Bio-Techne in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| HALO Halozyme Therapeutics, Inc. | $96.50 | $111.93 | +16.0% | Low evidence grade |
| BMRN BioMarin Pharmaceutical Inc. | $57.99 | $69.09 | +19.1% | Undervalued |
| TGTX TG Therapeutics, Inc. | $62.76 | $75.36 | +20.1% | Undervalued |
| KRYS Krystal Biotech, Inc. | $297.90 | $352.42 | +18.3% | Low evidence grade |
| PTGX Protagonist Therapeutics, Inc. | $124.83 | $104.97 | -15.9% | Overvalued |
| JAZZ Jazz Pharmaceuticals plc | $239.77 | $288.09 | +20.2% | Low evidence grade |
| CYTK Cytokinetics, Incorporated | $53.17 | $63.03 | +18.5% | Low evidence grade |
| NBIX Neurocrine Biosciences, Inc. | $165.31 | $171.92 | +4.0% | Fairly valued |
What the comparable companies' multiples alone would give for TECH, the peer-implied price, is $55.55 a share on this run. The fair value weighs that against the company's own multiple.
Bio-Techne at a glance
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
- Market value
- $11.4B
- Sector
- Healthcare
- Industry
- Biotechnology
- Revenue expected, next twelve months
- $1.3B
- Consensus revenue growth, next fiscal year
- +4.7%
- Analysts with estimates
- 5
- Beta to the US market
- 0.57
- First valued by Faircurve
- 1 May 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. TECH was not among them.
How the fair value is worked out: the model prices Bio-Techne on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for TECH was $65.04. As of 14 Nov 2026 it is $65.76, a change of +1.1%. Analysts raised their next-twelve-month EBITDA estimates: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Bio-Techne's valuation
Is Bio-Techne stock undervalued or overvalued?
On Faircurve's model, TECH reads as Fairly valued as of 14 Nov 2026. The model's fair value is $65.76 a share against a last close of $72.79, a gap of -9.7%.
What is TECH's fair value?
$65.76 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $52.93 to $81.53.
What price range does the model give TECH?
$52.59 to $78.12 over 63 trading days. Ranges built this way held the price 60% of the time across 13,250 past valuations, refreshed 14 Nov 2026.
When does Bio-Techne report earnings next?
The next report is scheduled for 2 Feb 2027. Companies can move their dates.
How much has TECH moved on past earnings reports?
Across its last 8 reports the median two session move was 0.2%, ignoring direction. The largest was -10.2% around the report of 6 May 2026.
How confident is the model in this valuation?
The model's evidence grade for TECH is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on TECH
The model holds no idea open on TECH today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on TECH with their outcomes. A free account is enough.